Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Making Sense Of The Latest Twists In The Twenty Year Agenus Saga
Seeking Alpha
Monday, August 26, 2013 - 12:00pm
tags:
Agenus
Alexza Pharmaceuticals: Stage Set For Adasuve
Seeking Alpha
Monday, August 26, 2013 - 10:46am
tags:
Alexza Pharmaceuticals, Adasuve, Teva Pharmaceuticals
Medtronic Is Changing Its Business. Will The System Let It?
Forbes
Monday, August 26, 2013 - 9:51am
tags:
Medtronic, devices, Cardiocom, patient monitors, M&A
Is There Any Substance To The Buyout Rumors Surrounding BioMarin And Catalyst?
Seeking Alpha
Monday, August 26, 2013 - 9:46am
tags:
M&A, Biomarin, Catalyst Pharmaceutical Partners
AstraZeneca forges $500M cancer-combo tech buyout for MedImmune
Fierce Biotech
Monday, August 26, 2013 - 9:34am
tags:
MedImmune, AstraZeneca, M&A
Ceptaris wins FDA OK for lymphoma gel, clears path to $250M Actelion buyout
Fierce Biotech
Monday, August 26, 2013 - 9:33am
tags:
Actelion, FDA, Ceptaris, Valchlor, cutaneous T-cell lymphoma
Study: More consumers turn to social media for health research
PharmaLive
Monday, August 26, 2013 - 9:30am
tags:
consumers, social media
Halt in Zilmax sales fuels demand for rival cattle feed product
Reuters
Monday, August 26, 2013 - 9:28am
tags:
Zilmax, Merck, Eli Lilly, animal health, Optaflexx
AstraZeneca to buy U.S. cancer firm for up to $500 mln
Reuters
Monday, August 26, 2013 - 9:26am
tags:
AstraZeneca, M&A, Amplimmune
Amgen to buy Onyx in deal worth $10.4 billion
Marketwatch
Monday, August 26, 2013 - 9:03am
tags:
Amgen, ONYX Pharmaceuticals, M&A
Sanofi Pasteur's Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older
Yahoo
Monday, August 26, 2013 - 8:08am
tags:
Sanofi Pasteur, Fluzone, vaccines, influenza
Rigel drops asthma drug after mid-stage study fails
Reuters
Monday, August 26, 2013 - 8:06am
tags:
Rigel, asthma, R343
China Biotech In Review: Eli Lilly Joins The Big Pharmas Accused Of Bribing In China
Seeking Alpha
Sunday, August 25, 2013 - 11:33am
tags:
Zhejiang Beta Pharma, BeiGene, Eli Lilly
Terminal Diagnosis: Despite What You May Have Heard, Dendreon Is A 'Dead Company Walking'
Seeking Alpha
Sunday, August 25, 2013 - 11:32am
tags:
Dendreon
A Time to Test Biotechs' Strength
The Street
Sunday, August 25, 2013 - 11:31am
tags:
Bluebird Bio, Epizyme, Intrexon, NanoString Technologies, LipoScience, Aratana, Heat Biologics, ONYX Pharmaceuticals, Amgen
Amgen Said to Be Near Agreement to Buy Onyx for $125 a Share
Bloomberg
Sunday, August 25, 2013 - 11:28am
tags:
Amgen, ONYX Pharmaceuticals, M&A
This Week in Biotech
Motley Fool
Sunday, August 25, 2013 - 11:27am
tags:
Supernus Pharmaceuticals, Novartis, Pain Therapeutics, GTx
Teva Shares Are Too Cheap
Barron's
Saturday, August 24, 2013 - 12:05pm
tags:
Teva Pharmaceuticals
Horizon Pharma Announces Settlement of Duexis Patent Litigation With Par Pharmaceutical
Healthcare Global
Saturday, August 24, 2013 - 12:04pm
tags:
Horizon, Par, Duexis, generics
Johnson & Johnson's 3 Most Promising Drugs (video)
Motley Fool
Saturday, August 24, 2013 - 12:00pm
tags:
Zytiga, Pharmacyclics, JNJ, Invokana, ibrutinib

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.